Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,449 shares of the biopharmaceutical company’s stock after selling 650 shares during the period. Sequoia Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,395,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. West Paces Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $37,000. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $40,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Truist Financial reissued a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $10.14 during mid-day trading on Friday, hitting $1,034.23. The stock had a trading volume of 418,302 shares, compared to its average volume of 436,890. The stock has a market capitalization of $113.96 billion, a price-to-earnings ratio of 30.55, a P/E/G ratio of 2.12 and a beta of 0.13. The company has a 50 day simple moving average of $998.19 and a 200-day simple moving average of $956.36. Regeneron Pharmaceuticals, Inc. has a 52 week low of $688.52 and a 52 week high of $1,081.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders have sold a total of 63,208 shares of company stock worth $62,514,142 in the last ninety days. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.